DE2935195A1 - Neues leberkontrastmittel und verfahren zu dessen herstellung - Google Patents

Neues leberkontrastmittel und verfahren zu dessen herstellung

Info

Publication number
DE2935195A1
DE2935195A1 DE19792935195 DE2935195A DE2935195A1 DE 2935195 A1 DE2935195 A1 DE 2935195A1 DE 19792935195 DE19792935195 DE 19792935195 DE 2935195 A DE2935195 A DE 2935195A DE 2935195 A1 DE2935195 A1 DE 2935195A1
Authority
DE
Germany
Prior art keywords
triiodo
ray contrast
acid
bis
liposomes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
DE19792935195
Other languages
German (de)
English (en)
Inventor
Nichtnennung Beantragt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
DAENIKER FELIX
Original Assignee
DAENIKER FELIX
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by DAENIKER FELIX filed Critical DAENIKER FELIX
Publication of DE2935195A1 publication Critical patent/DE2935195A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/04—X-ray contrast preparations
    • A61K49/0433—X-ray contrast preparations containing an organic halogenated X-ray contrast-enhancing agent
    • A61K49/0447—Physical forms of mixtures of two different X-ray contrast-enhancing agents, containing at least one X-ray contrast-enhancing agent which is a halogenated organic compound
    • A61K49/0461—Dispersions, colloids, emulsions or suspensions
    • A61K49/0466—Liposomes, lipoprotein vesicles, e.g. HDL or LDL lipoproteins, phospholipidic or polymeric micelles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
DE19792935195 1978-10-05 1979-08-31 Neues leberkontrastmittel und verfahren zu dessen herstellung Withdrawn DE2935195A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH1033378A CH641682A5 (en) 1978-10-05 1978-10-05 X-ray contrast medium

Publications (1)

Publication Number Publication Date
DE2935195A1 true DE2935195A1 (de) 1980-04-17

Family

ID=4362083

Family Applications (1)

Application Number Title Priority Date Filing Date
DE19792935195 Withdrawn DE2935195A1 (de) 1978-10-05 1979-08-31 Neues leberkontrastmittel und verfahren zu dessen herstellung

Country Status (3)

Country Link
CH (1) CH641682A5 (https=)
DE (1) DE2935195A1 (https=)
FR (1) FR2437831A1 (https=)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992021384A1 (en) * 1991-06-03 1992-12-10 Karlshamns Lipidteknik Ab X-ray contrast agent
US5593687A (en) * 1989-10-13 1997-01-14 Schering Aktiengesellschaft Aqueous dispersion containing liposomes

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2515960A1 (fr) * 1981-11-06 1983-05-13 Alkhouri Fallouh Nazir Nanocapsules ou nanoparticules biodegradables contenant une substance biologiquement active, leur preparation et leur application
CS255809B1 (en) * 1984-12-12 1988-03-15 Daniel Horak Rentgenocontrast spherical hydrogel particles on the base of polymers and copolymers acrylates and methacrylates and process for preparing them
US4680171A (en) * 1985-03-15 1987-07-14 William Shell Visualization of a bloodstream circulation with biodegradable microspheres
CH672733A5 (https=) 1987-05-22 1989-12-29 Bracco Ind Chimica Spa
WO1995026205A1 (en) * 1994-03-28 1995-10-05 Nycomed Imaging A/S Liposomes
DE4426439C1 (de) * 1994-07-26 1996-02-29 Schering Ag Kontrastmittel zur Darstellung der Leber
US6001333A (en) * 1997-09-12 1999-12-14 See; Jackie R. Methods of preparing micro encapsulated agents for use in the detection of tumors by CT imaging

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2613172A (en) * 1949-08-10 1952-10-07 American Cystoscope Makers Inc X-ray contrast compositions
US3356575A (en) * 1965-04-13 1967-12-05 Leo Ab Autosterile injectable iodinated oil X-ray contrast medium
DE2118219C3 (de) * 1971-04-10 1981-07-16 Schering Ag Berlin Und Bergkamen, 1000 Berlin Neues Röntgenkontrastmittel

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5593687A (en) * 1989-10-13 1997-01-14 Schering Aktiengesellschaft Aqueous dispersion containing liposomes
WO1992021384A1 (en) * 1991-06-03 1992-12-10 Karlshamns Lipidteknik Ab X-ray contrast agent
US5550263A (en) * 1991-06-03 1996-08-27 Karlshamns Lipidteknik Ab X-ray contrast agent

Also Published As

Publication number Publication date
CH641682A5 (en) 1984-03-15
FR2437831A1 (fr) 1980-04-30
FR2437831B1 (https=) 1983-03-25

Similar Documents

Publication Publication Date Title
DE69230144T2 (de) Röntgenkontrastmittel
DE2938807C2 (de) Intravenös verabreichbare Fettemulsion
DE69527194T2 (de) Liposomen enthaltend ein röntgen- oder ultraschallkontrastmittel
DE2404564C3 (de) Als Blutersatzmittel und Perfusionsflüssigkeit geeignete wässrige Emulsion und Verfahren zu ihrer Herstellung
EP0169299B1 (de) Verwendung von paramagnetischen Komplexsalzen zur Herstellung von Mitteln für die NMR-Diagnostik
DE69033560T2 (de) Arzneimittel für insulinresistente diabetiker
DE2814038C3 (de) Mit einem Radionuklid für radioaktive Tests markierbares Material
DE69534326T2 (de) Hepatocyt-selektive öl-in-wasser emulsion
EP0405704B1 (de) Derivatisierte DTPA-Komplexe, diese Verbindungen enthaltende pharmazeutische Mittel, ihre Verwendung und Verfahren zu deren Herstellung
DE3021006C2 (de) Oberflächenaktives Material und dieses Material enthaltendes pharmazeutisches Mittel gegen Hyalin-Membran-Erkrankung
CH657049A5 (de) Kuenstliches oberflaechenaktives mittel fuer die lunge und heilmittel fuer syndrome von atemnot, die dieses als aktive komponente enthalten.
DE2601207B2 (de) Verfahren zur Herstellung einer flüssigen pharmazeutischen Zubereitung mit gesteuertem Arzneimittelabgabevermögen
EP0131540A2 (de) Ultraschallkontrastmittel sowie dessen Herstellung
DE19709704A1 (de) Präparation, die gelöst oder dispergiert ein Gas mit einer pharmakologischen Wirkung enthält
DE3002004A1 (de) Kontrastmittel fuer die angiographie und verfahren zu ihrer herstellung
DE2935195A1 (de) Neues leberkontrastmittel und verfahren zu dessen herstellung
DE3785849T2 (de) Jod enthaltende emulsion.
EP0312108B1 (de) Mittel zur Kontrastierung von bösartigen Neubildungen bei ihrer Diagnostik
DE69021289T2 (de) Angiographisches Adjuvans.
DE60128800T2 (de) Hydrophobe iodverbindung enthaltende liposome
DE3515335A1 (de) Arzneizubereitung enthaltend dihydropyridine und verfahren zu ihrer herstellung
DE4310935A1 (de) Mikroemulsionen, deren Herstellung sowie Verwendung bei der Behandlung von Krebserkrankungen
EP0855186A2 (de) Gas enthaltende Mikropartikel, deren Verwendung in der Ultra-schalldiagnostik
EP0181287A2 (de) Trockensubstanzen und stabile Suspensionen
DE60006000T2 (de) Pharmazeutische zusammensetzungen zur oralen verabreichung

Legal Events

Date Code Title Description
8128 New person/name/address of the agent

Representative=s name: ULLRICH, T., DIPL.-CHEM. DR.RER.NAT., PAT.-ANW., 6

8139 Disposal/non-payment of the annual fee